Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Single-Centre, Open-Label, Repeat Dose Study to Assess the Pharmacokinetics, Safety and Tolerability Following Administration of Elafibranor in Healthy Japanese and Non-Asian Participants.

NCT05543369 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT05543369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05543369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Single-Centre, Open-Label, Repeat Dose Study to Assess the Pharmacokinetics, Safety and Tolerability Following Administration of Elafibranor in Healthy Japanese and Non-Asian Participants.
Lead sponsor
Ipsen
Phase
Phase 1
Overall status
Completed
Start date
September 19, 2022
Completion date
March 10, 2023
Enrollment
48 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers